MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody.

@article{Kinoshita2010MRMI,
  title={MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody.},
  author={Manabu Kinoshita and Yoshichika Yoshioka and Yoshiko Okita and Naoya Hashimoto and Toshiki Yoshimine},
  journal={Contrast media \& molecular imaging},
  year={2010},
  volume={5 1},
  pages={
          18-22
        }
}
In vivo molecular imaging is a rapidly growing research area both for basic and clinical science. Non-invasive imaging of in vivo conditions at the molecular level increases understanding of the biological characteristics of normal and diseased tissues without the need for invasive surgical procedures. Among the various imaging modalities, magnetic resonance imaging (MRI) has garnered interest as a molecular imaging modality due to its high spatial resolution. Here, we have demonstrated that… 
View on PubMed
cds.ismrm.org
41 Citations
Highly Influential Citations
2
Background Citations
12
Methods Citations
4

Figures from this paper

41 Citations

Citation Type

Citation Type

Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors.
TLDR
Her-2 targeted magnetic iron oxide nanoparticles are developed by conjugating a high affinity and small size HER-2 affibody that is labeled with a unique near infrared dye (NIR-830) to the nanoparticles, enabling non-invasive optical and MR imaging of tumors as small as 1 mm in the peritoneal cavity.
Current Limitations of Molecular Magnetic Resonance Imaging for Tumors as Evaluated With High-Relaxivity CD105-Specific Iron Oxide Nanoparticles
TLDR
Molecular MRI by targeted SPIOs is currently not suitable for clinical tumor imaging using routinely applicable sequences and field strength despite being addressed in the literature several times in the last 20 years.
Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy
TLDR
The new ‘image and treat’ strategy, involving assessment of target presence and distribution in an individual patient followed by optimized, target-specific drug delivery, may potentially improve efficacy of cancer treatment while reducing side effects.
Current limitations of molecular MRI for tumors as evaluated with high relaxivity CD105-specific iron oxide nanoparticles
TLDR
It is postulate that MRI using clinical sequences and field strengths and targeted SPIOs is not suitable for clinical tumor imaging.
Preclinical and clinical applications of specific molecular imaging for HER 2-positive breast cancer
TLDR
This work reviewed existing literature on HER2 imaging in the past decade and summarized the studies from different points of view, such as imaging modalities and HER2-specific probes to improve the understanding on the translational process in molecular imaging for HER2 breast cancer.
Design and evaluation of radiolabeled tracers for tumor imaging
TLDR
The concept of molecular targeting and, in particular, molecular imaging of cancer‐associated targets are discussed and important biotechnological considerations and desired features when designing and developing tracers for radionuclide molecular imaging are described.
Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
TLDR
This work reviewed existing literature on HER2 imaging in the past decade and summarized the studies from different points of view, such as imaging modalities and HER2-specific probes to improve the understanding on the translational process in molecular imaging for HER2 breast cancer.
Molecular Imaging Probes for Diagnosis and Therapy Evaluation of Breast Cancer
TLDR
Current molecular imaging probes involved in breast cancer diagnosis and therapy evaluation are reviewed, and future of molecular imaging for the preclinical and clinical is explained.
Chemical and Biological Strategies for Improving the Sensitivity of SPIO-Enhanced MR Imaging
TLDR
By controlling and altering surface functionalization of SPIO nanoparticles, it is found that this work is able to significantly improve its ability to target tumor cells both in vitro and in murine tumor models, often overcoming the relatively poor sensitivity of MRI.
In vivo near-infrared imaging of ErbB2 expressing breast tumors with dual-axes confocal endomicroscopy using a targeted peptide
TLDR
Real-time optical sectioning using a near-infrared labeled ErbB2 peptide that generates tumor-specific contrast in human xenograft breast tumors in vivo is demonstrated and peptide biodistribution showed high tumor uptake by comparison with other organs to support safety.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging
TLDR
The results suggest that Affibody-Alexa Fluor conjugates may be used as a specific NIR probe for the noninvasive semiquantitative imaging of HER2 expression in vivo.
Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
TLDR
A HER2-specific 6 kDa Affibody molecule with 22 pmol/L affinity that can be used for the visualization of HER2 expression in tumors in vivo using gamma camera is described and shows clear, high-contrast visualization of Her2-expressing xenografts in mice as early as 6 hours post-injection.
In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma
On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model
TLDR
The use of the small scaffold targeting Affibody provides better contrast in HER2 imaging than does the monoclonal antibody.
A new transgene reporter for in vivo magnetic resonance imaging
TLDR
A new platform technology for visualizing transgene expression in living subjects using magnetic resonance imaging (MRI) using a vector, where the cells construct the MRI contrast agent in situ using genetic instructions introduced by the vector, thereby simplifying intracellular delivery.
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
TLDR
The present results show that radiolabeled synthetic DOTA-Z(HER2:342-pep2) has the potential to become a clinically useful radiopharmaceutical for in vivo molecular imaging of HER2-expressing carcinomas.
MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter
TLDR
MRI shows that these particles can be formed in vivo utilizing endogenous iron and can be used to visualize cells positive for magA, and demonstrates that magA alone is sufficient to produce magnetic nanoparticles.
In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide
TLDR
In vivo detection of VCAM-1 in acute brain inflammation is reported by magnetic resonance imaging in a mouse model, at a time when pathology is otherwise undetectable, and antibody-conjugated microparticles carrying a large amount of iron oxide provide potent, quantifiable contrast effects that delineate the architecture of activated cerebral blood vessels.
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
TLDR
Increased hydrophilicity, combined with improved stability of the mercaptoacetyl-triglutamyl chelator, resulted in favorable biodistribution, making (99m)Tc-maEEE-Z(HER2:342) a promising tracer for clinical imaging of HER2 overexpression in tumors.
Assessment of a potential tumor‐seeking manganese metalloporphyrin contrast agent in a mouse model
TLDR
HOP‐8P is a promising tumor‐seeking metalloporphyrin MR contrast agent with a wide imaging window and was consistently cleared from the circulation, liver, kidneys, and muscle; however, it was progressively accumulated within the tumor.
...
1
2
...